Aleva Neurotherapeutics, a leading developer of implants for deep brain stimulation (DBS) in major neurological indications such as Parkinson’s disease and essential tremor, today announced that it has been awarded the CE Mark for its flagship product, the...
AMOÉBA (FR0011051598 – AMEBA), producer of a biological biocide, capable of eliminating bacterial risk in water and human wounds, and a biocontrol product for plant protection, still in the testing phase, announces a major scientific publication. As the result...
Diabeloop announced today that it has completed a 31-million-euro Series B round of funding, setting a European fundraising record in the area of therapeutic artificial intelligence.This funding will allow Diabeloop to accelerate its international commercial...
Recent Comments